AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: http://hdl.handle.net/11055/1022
Title: High-dose intravenous immunoglobulin is effective diabetic polyneuropathy resistant to conventional treatments. Results of a double-blind, randomized, placebo-controlled trial: comments
Authors: Wee, TC
Yeow, LT
ANZCA/FPM Author: Wee, TC
Keywords: Diabetes
Pain management
Immunoglobulin
Issue Date: 20-Mar-2020
Abstract: We read with interest a recent publication by Jann et al., “High-Dose Intravenous Immunoglobulin Is Effective Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled Trial” [1]. The results suggest intravenous immunoglobulin (IVIG) as a promising pain treatment modality for this group of patients. Although the study methodology has provided a detailed outline of its population recruitment, there was no information regarding the severity of diabetes and diabetic control, in terms of micro- and macrovascular complications and HbA1c levels. Better glycemic control is known to reduce the incidence of clinical neuropathy, although its impact on pain is unknown [2]. Nevertheless, improvement in diabetic control during the course of the study remains a potential confounder and may have an influence on the symptoms of DPN.
URI: http://hdl.handle.net/11055/1022
DOI: 10.1093/pm/pnaa057
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/32196108
ISSN: 1526-2375
Journal Title: Pain Medicine
Type: Journal Article
Affiliates: Changi General Hospital
Singapore General Hospital
Study/Trial: Letter
Appears in Collections:Scholarly and Clinical

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.